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The procedure for the techniques of extracorporeal 
support of vital functions (Extracorporeal Membrane 
Oxygenation) can be an effective therapeutic tool 
for critically ill patients [1]. The application of this 
method within the COVID-19 pandemic, however, is 
only possible with adequate medical personnel and 
equipment [2]. COVID-19 is a disease caused by the 
new SARS-CoV-2 virus that appeared in December 
2019 and has now become a worldwide pandem-
ic with rapid spread [3]. On April 21, there were 
2.497.000 confirmed cases with 656.051 recovered 
patients and, unfortunately, 171.245 deaths. In Po-
land, which has more than 38 million inhabitants, 
there were 9.737 confirmed cases and 385 deaths, 
and the USA with 328 million inhabitants with con-
firmed 793.000 cases, 42.518 deaths, and 72.390 re-
covered patients [4–6]. The spectrum of the SARS-
CoV-2 associated pneumonia is mild to life-threaten-
ing critical situations and requiring critical treatment. 
Reports indicate that most COVID-19 patients have 
moderate symptoms (fever, cough and fatigue) and 
recover quickly, however, group of patients develop 
severe respiratory failure and acute respiratory dis-
tress syndrome (ARDS) necessitating intensive care. 
Unfortunately, the death rate of COVID-19 requiring 
mechanical ventilation is high. ECMO can be a life-
saving measure for patients with severe ARDS or 
refractory cardiovascular disease [7–9].
ECMO is a method of extracorporeal membrane 
blood oxygenation implemented via an oxygenator 
responsible for gas exchange and pumps for blood 
circulation. Depending on the technique, the device 
is connected to the patient’s vessels, and used to 
support the insufficient respiratory system — ECMO 
VV venous-venous or the insufficient circulatory and 
respiratory systems — ECMO VA — venous-arterial. 
The ECMO is not treatment but support technique, it 
offers the prospect of prolonging the time of therapy 
and regeneration of insufficient systems [10, 11].
ECMO is an invasive therapy with a high risk 
of sudden and severe life-threatening complications 
(disconnection of the system, dislocation of can-
nulas, air embolism). For this reason, a constant 
presence of at least two medical personnel trained in 
ECMO therapy is necessary. When planning the care 
for a patient with suspected or confirmed infection 
with the SARS-CoV-2 virus, the balance between the 
potential benefits of ECMO and the available person-
nel (with appropriate experience and training) as well 
as hospital equipment (including personal protective 
equipment) and infrastructure should be explicitly se-
cure [2, 8, 12]. The risk to medical personnel and the 
need to care for other critically ill patients should also 
be taken into account. This is particularly essential, as 
it becomes challenging to work in complicated and 
advanced PPE for the personnel of Intensive Care 
Units, who are required to spend prolonged periods 
with a patient connected to the ECMO device [13]. 
In critical patients, mechanical ventilation is the 
primary method of supportive therapy. In the case of 
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SARS, a vital element of the procedure is additionally 
the low-pressure ventilation schemes with low tidal 
volume ventilation (Vt) (Vt 4–8 ml/kg of predict-
ed body weight) and pressure plateau orientation 
(Pplat) < 30 cm H2O and a higher positive end pres-
sure strategy exhaust. This is utilized to minimize 
lung damage caused by respiratory therapy [14]. To 
minimize the potential for lung damage, and when 
there is a lack of available ventilation equipment, 
ECMO becomes useful in the treatment of COV-
ID-19 patients [15]. The ELSO report shows that 
during the advancement of the pandemic there was 
an increase in the use of the ECMO therapy, and at 
the time of writing this letter, 901 patients were sup-
ported by ECMO (average age is 52 years, 95% VV 
ECMO, 5% VA ECMO and other configurations) [3].
Currently, in Poland, five centers have been se-
lected to meet the challenges of using ECMO VV 
for COVID-19 patients. The application of ECMO 
therapy during the COVID-19 pandemic is challeng-
ing yet achievable, offering a high chance of pa-
tient survival.
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